Redknee Announces Standby Purchase Agreement in Furtherance of its Strategic Plan

Redknee Solutions Inc. (“Redknee” or the “Company”) (TSX: RKN) has announced that it has entered into a Standby Purchase Agreement with Wave Systems Corp. (“Wave”), an affiliate of ESW Capital, LLC (“ESW”), and ESW in connection with the launching of an approximately US$54 million rights offering, fully backstopped by Wave (the “Rights Offering”). The net proceeds of the Rights Offering will be used to fund a restructuring of the business (the “Restructuring”) in furtherance of the previously announced strategic plan (the “Strategic Plan”) which will, among other things, create a strong platform for long-term growth, simplified operations and sustained profitability for the Company. The Company is also announcing certain leadership changes in connection with the Restructuring.

Subject to the closing of the Rights Offering, the Company will enter into (i) a services agreement with Crossover Markets, Inc. (“Crossover”) pursuant to which Crossover will provide the Company with access to service providers (the “Crossover Services Agreement”), and (ii) a technology services agreement with DevFactory FZ-LLC (“DevFactory”) pursuant to which DevFactory will provide certain technology services to the Company (the “DevFactory Services Agreement” and, together with the Crossover Service Agreement, the “Services Agreements”). The Company has extended the interim Services Agreements with Crossover and DevFactory to the earlier of (i) the Special Meeting referred to below, if the necessary shareholder approvals are not obtained, and (ii) the termination of the Standby Purchase Agreement. Crossover and DevFactory are affiliates of ESW.

Entering into the Standby Purchase Agreement represents the outcome of a review of alternatives undertaken by a special committee of independent directors (the “Special Committee”) of the board of directors of the Company (the “Board”), comprised of Mr. Keith Graham (chair), Ms. Christina Jones and Mr. Farhan Thawar (the “Independent Directors”). The Special Committee was advised by TD Securities Inc., as financial advisor, and Goodmans LLP, as legal advisor. The Special Committee, with the assistance of its advisors, has determined that the Rights Offering, the Standby Purchase Agreement and the Services Agreements collectively represent the best available alternative for the Company.


Helsinn Group and Purdue Pharma (Canada) has announced that they have signed a distribution and licence agreement granting Purdue Pharma (Canada) exclusive rights to distribute, promote, market and sell ALOXI® (palonosetron hydrochloride) in Canada.

ALOXI® is an anti-emetic (5-HT3 receptor antagonist) authorized for sale by Health Canada in adults for the prevention of chemotherapy-induced nausea and vomiting (CINV)I.

ALOXI® is approved in over 70 countries worldwide, including the United States, European countries and Japan.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “ALOXI® has helped to provide relief from CINV to patients across the world and, through this agreement with Purdue Pharma (Canada) we hope to extend its benefits to a greater number of patients in Canada. We are also pleased to be able to broaden our relationship with Purdue/Mundipharma Network, a trusted partner that we work with in many countries across 5 continents and look forward to working with them in Canada”.

Dr. Craig Landau, Purdue Pharma (Canada) CEO added: “Patients deserve access to medicines and treatments that help them manage their symptoms so they can participate fully in the things that matter most to them. Purdue Pharma (Canada) already offers medicines that benefit patients with cancer who also suffer from pain. Now, we can also help those who suffer from CINV. ALOXI® is a natural addition to our expanding portfolio.”

PotashCorp Teams Finish on Top in Mine Rescue Competition

For the fourth straight year, PotashCorp Patience Lake has won the Surface Division of the Saskatchewan Emergency Response/Mine Rescue Skills Competition.

This is the 10th time in 13 years that Patience Lake has won this category.

PotashCorp Lanigan was runner-up this year in the underground division. Lanigan also has a history of success in the competition; it took the underground title in 2016 and 2015 and was runner-up in 2014.

A total of 15 teams competed in 2017: nine in the underground division and six in surface. Teams are tested in five areas: Fire Fighting, First Aid, Proficiency Skills (which includes a written exam), Practical Skills and response to simulated Surface and Underground Mine Problems.

The events test miners’ abilities and knowledge in emergency situations that can arise at their sites.

“Our mine rescue teams are a critical part of our potash operations. It’s absolutely necessary to have trained, knowledgeable responders if the need arises,” said Mark Fracchia, President, PCS Potash. “We appreciate each employee who steps up for this role. The mine rescue competition is a challenging test of their skills and we are proud of the expertise shown by all our teams.”

Here is the full list of results:

Surface Winner: PotashCorp Patience Lake
Surface Runner-Up: Cameco Key Lake
Underground Winner: Mosaic Esterhazy K1
Underground Runner-Up: PotashCorp Lanigan


Surface Winner: Cameco Key Lake
Surface Runner-Up: Mosaic Belle Plaine

Underground Winner: PotashCorp Rocanville
Underground Runner-Up: Mosaic Esterhazy K1

Surface Winner: PotashCorp Patience Lake
Surface Runner-Up: Westmoreland Coal Poplar River
Underground Winner: PotashCorp Lanigan
Underground Runner-Up: Mosaic Esterhazy K2

Surface Winner: AREVA Resources McLean Lake
Surface Runner-Up: Mosaic Belle Plaine
Underground Winner: PotashCorp Allan
Underground Runner-Up: Silver Standard Seabee

Surface Winner: Westmoreland Coal Poplar River
Surface Runner-Up: PotashCorp Patience Lake
Underground Winner: PotashCorp Lanigan
Underground Runner-Up: Mosaic Esterhazy K1

Surface Winner: Mosaic Belle Plaine
Surface Runner-Up: Cameco Key Lake
Underground Winner: Mosaic Esterhazy K1
Underground Runner-Up: PotashCorp Allan

PointClickCare and ABILITY Network Combine Strengths to Help LTPAC Providers Get Paid Faster

PointClickCare, the leading cloud-based software platform for the senior care continuum and ABILITY Network, a leading information technology company are teaming up to simplify and reduce the effort required for claims management. Working directly within the PointClickCare platform and leveraging the ABILITY | EASE® All-Payer workflow application, providers will have a single integrated solution to create, access, and manage all claims from within the electronic health record (EHR) – eliminating the need for multiple systems and laborious manual processes.

“Manually managing claims and reimbursement can be a headache for clinicians and administrators,” said Bud Meadows, executive vice president and chief revenue officer of ABILITY Network. “As the vendor of choice for PointClickCare, ABILITY will help providers on the PointClickCare EHR platform simplify the complexity of billing, leveraging EASE® All-Payer. There is no jumping between systems, having to check and recheck varied documents to see the status of a claim – it is all built into the EHR. Having all the information at the ready makes for higher accuracy in claims, which ultimately leads to quicker reimbursement.”

Combining ABILITY’s RCM application within PointClickCare’s EHR platform will help providers manage and correct claims before transmission to the payer, and have any changes or status information communicated directly back to the EHR. All information will be available within one system and in real-time and will provide users with more accurate rules validation, faster and easier corrections, and integration with eligibility verification, all adding up to quicker reimbursement for a healthier bottom line.

“We are always looking for ways to improve our customers’ experience with our platform, and working with ABILITY Network allows us to offer our customers access to the critical tools they need to improve their business processes,” said Matt D’Angelo, vice president, Financial Product Management at PointClickCare. “We understand that one of the biggest challenges our customers can face is the claims management process, and with ABILITY’s expertise we’re going to be able to simplify the financial complexities of healthcare for care providers.”

Recognized by Forbes in 2016 as two of the top 100 Cloud Companies, PointClickCare and ABILITY Network are committed to delivering applications that will simplify complexity, increase efficiency and help their customers achieve the business results that matter most to them.

Pfizer Canada supports inclusive sports opportunities through 2017 #ParaFlipFlop campaign

Pfizer Canada Inc. is joining forces with the Paralympic Foundation of Canada to raise funds to ensure that Canadians of all abilities have access to sport opportunities.

From June 16 to July 16, 2017, the company will donate $10* to the Paralympic Foundation of Canada for every pair of 2017 #ParaFlipFlops purchased here. These funds are in addition to 30% of sales for every pair of $15 #ParaFlipFlops sold online or in store at Hudson’s Bay. As the newly established philanthropic arm of the Canadian Paralympic Committee, the Paralympic Foundation of Canada’s goal is to ensure that the programs, equipment and people are in place to propel more Canadians with a disability all the way from the playground to the Paralympic podium.

“Many Canadians with a disability have not been given the opportunity to become athletes. Sport not only helped me become the person I am today, it gave me the opportunity to be an elite athlete competing on the world stage, allowed me to have a healthy lifestyle, and gave me the chance to find balance and purpose in my life,” says Benoit Huot, five-time Paralympic swimmer and winner of 20 Paralympic medals.

After more than 20 years of partnership, Pfizer Canada Inc. is proud to be one of the Canadian Paralympic Committee’s longest standing partners. The partnership focuses on the health benefits of inclusive sports opportunities for all Canadians and supports the next generation of athletes.

“Physical activity offers people the opportunity to boost their self-esteem and prevents many health conditions that affect people of all abilities, such as depression, fatigue and obesity,” explains Rhonda O’Gallagher, Vice-president, Corporate Affairs, Pfizer Canada Inc. “We believe every Canadian should be encouraged to reach their full potential by participating in sport, regardless of ability.”

Pacific Announces Name Change To Frontera Energy Corporation

Pacific Exploration & Production Corporation has announced that it has changed its corporate name to Frontera Energy Corporation (the “Company” or “Frontera”) to mark the beginning of a new era for the Company. The Company’s common shares are expected to commence trading on the Toronto Stock Exchange under the new name and ticker symbol TSX:FEC at the opening of trading on Wednesday, June 14, 2017. Frontera’s vision is to build on its position as a focused, low cost, exploration and production company and to create maximum value for all stakeholders. Frontera is also committed to the health, safety and success of its employees and is dedicated to the relationships it builds with suppliers, partners, governments and the communities in which it operates.

Barry Larson, Chief Executive Officer of Frontera Energy Corporation, commented:

“Our new corporate identity reflects the significant transformation the Company has made following its restructuring, as well as a new progressive and disciplined focus that will generate success. To ensure the Company can maintain sustainable production and growth, the Board has taken steps to narrow Frontera’s geographic focus and reduce organizational scale, complexity and cost while maximizing operating and cost efficiencies. The Company has a renewed culture and deep-rooted values, with an emphasis on health, safety and environment, which have been embraced and embodied by our workforce. By staying true to the core values of Integrity, Respect, Commitment and Sustainability, Frontera is well equipped to move forward into a new era of prosperity.”

Gabriel de Alba, Chairman of the Board of Directors of Frontera Energy Corporation, commented:

“Frontera is a competitive low-cost producer and will maintain a market leadership position over the long-term by staying disciplined and margin-focused, not simply production-driven. The Company has a renewed strategic focus, positive cash flow, a strong balance sheet, significantly reduced payables, and has a Board of Directors with the unique skills and experience needed to guide management and drive value creation for all stakeholders.”

The Company’s strategic direction is driven by Frontera’s Four Pillars of Value Creation:

1. Successful Restructuring

Successful debt restructuring creates a strong balance sheet and a renewed focus on constant improvement across the organization
New Board of Directors and Management team committed to the highest standards of corporate governance with a focus on value creation and disciplined growth
2. Ongoing Turnaround

Continuing to optimize corporate structure to realize savings in G&A and OPEX
Constant effort at margin improvement, management of overhead and creating operating efficiencies
3. Production Growth and Exploration Upside

Narrowing the Company’s geographic focus, reducing organizational scale, complexity and cost
High graded activity set with focus on value, not volume
Optimizing our plan for organic production growth through exploration and development drilling in highly prospective areas
4. Unlocking Value

Divestment strategy focused on non-core low prospectivity assets to reduce future exploration commitments and improve liquidity
Capture the potential of high value infrastructure assets
Frontera’s cultural identity is built upon the Company’s core values:

INTEGRITY – Lead by example, act consistently and transparently, and maintain open and clear dialogue in all engagements

RESPECT – Value inclusion and diversity, learn from experience and value all points of view

COMMITMENT – Demonstrate accountability for decisions, work together to achieve goals, and strive for excellence through innovation, adaptation and learning

SUSTAINABILITY – Preserve and care for the well-being of employees and contractors, promote safety in all operations, promote and protect social, economic and environmental value creation, and engage positively with all stakeholders
The new name is effective immediately, and will be implemented throughout the Company for the remainder of the 2017 calendar year. The Company’s new website can be found at

The Company has made an application to the Toronto Stock Exchange for its approval of the name change and has received conditional approval subject to the submission of the required final documentation.

No action is required to be taken by the Company’s shareholders in connection with the name change.

Davigel Selects the OpenText Cloud to Manage Global Invoicing

OpenText™ (NASDAQ: OTEX, TSX: OTEX), a global leader in Enterprise Information Management (EIM) has announced that Davigel, a leading provider of branded frozen and chilled food products, has selected OpenText to manage critical invoice compliancy with its customers. Using OpenText Active Invoices with Compliance, the company can now automate time-consuming invoicing processes to cut processing times, simplify workflows, and assist with compliance.

Previously owned by Nestlé, Davigel was acquired by the London-based Brakes Group in 2015. Following the acquisition, Davigel selected OpenText Managed Services to migrate their trading partner community of customers and logistics providers from Nestlé to its own B2B trading platform without any limiting business disruption and project risk. Building on the success of its B2B project, Davigel has expanded its relationship with OpenText to deploy a secure e-billing solution with OpenText Active Invoices with Compliance.

“OpenText is a trusted partner, and the success of our existing project is the proof,” said Paul Lavoquet, CIO, BCED. “We were looking for a reliable partner offering a single solution to maintain compliance for electronic billing with our customers located mainly in France and in a 12-month term with our customers based out of France.”

A key factor in electronic billing is ensuring that each generated invoice is compliant with local regulations, and it is a complex challenge for businesses. With approximately 120,000 invoices issued per year in France across the commercial, social and airline catering sectors, OpenText helped Davigel to ensure compliance at a fiscal level according to the French law.

“Every country in the world has legislation to regulate electronic invoicing. While regulations are often similar in purpose, the specific requirements can vary significantly by country,” said Lavoquet. “Data archiving requirements vary between six to eleven years depending on which countries are involved with the invoice. For Davigel, doing business with customers in different countries which have VAT, the challenges are multiplied as we must manage country-specific VAT, security, and archiving requirements for every country we support. OpenText Active Invoices with Compliance helped us to achieve these expectations.”

OpenText™ Active Invoices with Compliance is an e-Invoicing compliance solution, which provides organizations with the capabilities to automate e-Invoicing and compliance in more than 45 countries. Compatible with OpenText B2B Managed Services, Active Invoices with Compliance supports data validation, digital signatures, archiving and delivery. A simple, intuitive web portal provides access for any employees and auditors who must access the archive.

Combination treatment PrTafinlar® (dabrafenib) plus PrMekinist® (trametinib) approved by Health Canada to treat BRAF V600-positive metastatic non-small cell lung cancer (NSCLC) after prior systemic therapy

A combination oral drug treatment from Novartis has been approved by Health Canada to treat a form of non-small cell lung cancer (NSCLC). Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) has been approved for the treatment of patients with metastatic NSCLC with a BRAF V600 mutation whose disease has progressed following systemic therapy1. It is estimated that about 1-3% of Canadians with NSCLC are BRAF V600-positive2, a population who previously had few treatment options3.

“We are very pleased to be able to offer a new treatment option to this specific population of Canadians with lung cancer,” said Winselow Tucker, General Manager of Novartis Canada Oncology. “We recognize the significance of this news for the lung cancer community. Novartis remains committed to ongoing research and development of new innovative therapies to meet the needs of Canadians with various types of cancer.”

Tafinlar® and Mekinist® target different proteins, BRAF and MEK1/2 respectively, from a signaling pathway1 which is implicated in NSCLC4 and melanoma1. When Tafinlar® is used with Mekinist®, the combination has been shown to slow tumor growth more than either drug alone1,5.

“As we learn more about the different types of lung cancer and their specific molecular and genetic nature, targeted therapies become vital to have the best chance of treatment success,” said Dr. Barbara Melosky, medical oncologist at the BC Cancer Agency. “This new combination treatment has shown promising results in clinical studies and gives patients hope and an important new option where before the treatments were limited.”

Lung cancer is by far the deadliest cancer in Canada, claiming almost 21,000 Canadians in 2016, more than colorectal, breast and prostate cancer combined6.

“The availability of a targeted therapy specifically for NSCLC patients with a BRAF V600 mutation is great news,” said Shem Singh, Executive Director, Lung Cancer Canada. “New treatments give cancer patients and their families a chance to live and spend more quality time together. Health Canada approval is the first step. We hope Canadians who stand to benefit from this combination treatment can get access and have the chance it offers.”

About Tafinlar® + Mekinist® Combination

The Tafinlar® + Mekinist® combination was previously approved for the treatment of unresectable or metastatic melanoma with a BRAF V600 mutation1. Tafinlar® and Mekinist® are also indicated as single agents to treat patients with unresectable or metastatic melanoma with a BRAF V600 mutation1.

The combination of Tafinlar® + Mekinist® is currently being investigated in an ongoing clinical trial program across a range of tumor types conducted in study centers worldwide. The safety and efficacy profile of the Tafinlar® + Mekinist® combination has not yet been established outside of the approved indications.

Novartis Commitment to Oncology

At Novartis, our mission is to discover new ways to help improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop innovative treatments and find new ways to deliver them to as many people as possible. We strive to change the practice of medicine. We aspire to approach things differently – to make discoveries that take medicine in new directions. We look to tomorrow to inspire us today. Never satisfied with the status quo, we imagine what’s next.

As one of the leading pharmaceutical companies in oncology, Novartis globally offers a portfolio of more than 20 approved therapies and approximately 30 compounds in development. We are passionate about what we do and the impact we have on patients and societies. We are Novartis, and we are reimagining medicine.